Pharmacokinetics of valproic acid after administration of three oral formulations in healthy adults
- PMID: 2266076
Pharmacokinetics of valproic acid after administration of three oral formulations in healthy adults
Abstract
The pharmacokinetics and bioavailability of valproic acid was compared in six healthy volunteers after single dose oral administration of 400 mg of the drug in tablet, capsule and syrup form in a crossover manner. Blood samples were collected for 48 hours and valproic acid concentration analysed by enzymatic immunoassay. Following the administration of the three dosage forms, the absorption varied (Ka = Syrup K 2.64 +/- 0.5; tablet 1.57 +/- 0.22; and capsule 0.55 +/- 0.55 h-1). Valproic acid concentration reached a peak level of 102.3 micrograms.ml at 1.9 h after syrup administration, 73 micrograms/ml at 3.3 h after tablet and 44.8 micrograms/ml at 5.4 h after capsule. The bioavailability of tablet and syrup formulation was not significantly different from each other but it differed from capsule form in that the bioavailability was only 52%.
Comment in
-
Sodium valporate formulations.J Assoc Physicians India. 1991 Jun;39(6):504-5. J Assoc Physicians India. 1991. PMID: 1938863 No abstract available.
Similar articles
-
Pharmacokinetics of valproic acid obtained after administration of three oral formulations to humans.Isr J Med Sci. 1984 Jan;20(1):46-9. Isr J Med Sci. 1984. PMID: 6421770
-
Bioavailability of indomethacin tablets in men volunteers.Clin Pharm. 1986 Oct;5(10):820-4. Clin Pharm. 1986. PMID: 3780150
-
Pharmacokinetic characteristics of a new multiple unit sustained release formulation of sodium valproate.Int J Clin Pharmacol Ther. 1999 Feb;37(2):100-8. Int J Clin Pharmacol Ther. 1999. PMID: 10082174
-
Clinical pharmacokinetics of valproic acid--1988.Clin Pharmacokinet. 1988 Dec;15(6):367-89. doi: 10.2165/00003088-198815060-00002. Clin Pharmacokinet. 1988. PMID: 3149565 Review.
-
[Chronopharmacology and DDS (drug delivery system)].Nihon Rinsho. 1993 Oct;51(10):2778-87. Nihon Rinsho. 1993. PMID: 8254954 Review. Japanese.
Cited by
-
Physiologically-Based Pharmacokinetic Modeling of Total and Unbound Valproic Acid to Evaluate Dosing in Children With and Without Hypoalbuminemia.Clin Pharmacokinet. 2024 Oct;63(10):1435-1448. doi: 10.1007/s40262-024-01418-8. Epub 2024 Sep 19. Clin Pharmacokinet. 2024. PMID: 39298079
-
Population pharmacokinetics of unbound valproic acid in pediatric epilepsy patients in China: a protein binding model.Eur J Clin Pharmacol. 2021 Jul;77(7):999-1009. doi: 10.1007/s00228-020-03080-y. Epub 2021 Jan 10. Eur J Clin Pharmacol. 2021. PMID: 33423079
-
A population pharmacokinetic model of valproic acid in pediatric patients with epilepsy: a non-linear pharmacokinetic model based on protein-binding saturation.Clin Pharmacokinet. 2015 Mar;54(3):305-17. doi: 10.1007/s40262-014-0212-8. Clin Pharmacokinet. 2015. PMID: 25388986
-
Factors associated with subtherapeutic levels of valproic acid in hospitalized patients with epilepsy: A retrospective cohort study.Medicine (Baltimore). 2024 Nov 8;103(45):e40488. doi: 10.1097/MD.0000000000040488. Medicine (Baltimore). 2024. PMID: 39533583 Free PMC article.
-
Physiologically based pharmacokinetic modeling of disposition and drug-drug interactions for valproic acid and divalproex.Eur J Pharm Sci. 2018 Jan 1;111:465-481. doi: 10.1016/j.ejps.2017.10.009. Epub 2017 Oct 10. Eur J Pharm Sci. 2018. PMID: 29030176 Free PMC article.